Review



anti phosphorylated iκb  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Proteintech anti phosphorylated iκb
    Anti Phosphorylated Iκb, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 83 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phosphorylated iκb/product/Proteintech
    Average 94 stars, based on 83 article reviews
    anti phosphorylated iκb - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    94
    Proteintech anti phosphorylated iκb
    Anti Phosphorylated Iκb, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phosphorylated iκb/product/Proteintech
    Average 94 stars, based on 1 article reviews
    anti phosphorylated iκb - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    96
    Proteintech phosphorylated iκb alpha
    Phosphorylated Iκb Alpha, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated iκb alpha/product/Proteintech
    Average 96 stars, based on 1 article reviews
    phosphorylated iκb alpha - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    94
    Proteintech phosphorylated iκb
    Phosphorylated Iκb, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated iκb/product/Proteintech
    Average 94 stars, based on 1 article reviews
    phosphorylated iκb - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc primary antibodies against phosphorylated- iκb (p-iκb)
    Primary Antibodies Against Phosphorylated Iκb (P Iκb), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against phosphorylated- iκb (p-iκb)/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against phosphorylated- iκb (p-iκb) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    ABclonal Biotechnology antibody phosphorylated iκb (piκb)
    Effects of BCL on FcRn and related transcription factor expression and ANCA recycling in NCM460 cells. (a,b) FcRn mRNA and protein contents in NCM460 cells with gradient concentrations of BCL treatment for 48 h. Cells with a blank medium treatment were set as a control. (c) Relative recycling of ANCA in NCM460 cells after treatment with the blank medium or 40 μM BCL for 48 h. The relative recycling was calculated with the amount recycled for ANCA compared to that of the control. (d) mRNA contents of <t>p50,</t> p65, IκB, and STAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. (e) Protein contents of p50, p65, IκB, pIκB, STAT1, and pSTAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. All data are expressed as the mean ± SD ( n = 3 replicates/treatment). The protein expression of p50, p65, IκB, pIκB, STAT1, pSTAT1, and the protein/mRNA expression levels of FcRn were normalized to those of GAPDH or β-actin. n.s represents the differences that were not statistically significant ( p > 0.05). */# represent p < 0.05; ** represents p < 0.01; *** represents p < 0.001 against the control.
    Antibody Phosphorylated Iκb (Piκb), supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody phosphorylated iκb (piκb)/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    antibody phosphorylated iκb (piκb) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc phosphorylated iκb α
    Effects of BCL on FcRn and related transcription factor expression and ANCA recycling in NCM460 cells. (a,b) FcRn mRNA and protein contents in NCM460 cells with gradient concentrations of BCL treatment for 48 h. Cells with a blank medium treatment were set as a control. (c) Relative recycling of ANCA in NCM460 cells after treatment with the blank medium or 40 μM BCL for 48 h. The relative recycling was calculated with the amount recycled for ANCA compared to that of the control. (d) mRNA contents of <t>p50,</t> p65, IκB, and STAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. (e) Protein contents of p50, p65, IκB, pIκB, STAT1, and pSTAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. All data are expressed as the mean ± SD ( n = 3 replicates/treatment). The protein expression of p50, p65, IκB, pIκB, STAT1, pSTAT1, and the protein/mRNA expression levels of FcRn were normalized to those of GAPDH or β-actin. n.s represents the differences that were not statistically significant ( p > 0.05). */# represent p < 0.05; ** represents p < 0.01; *** represents p < 0.001 against the control.
    Phosphorylated Iκb α, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated iκb α/product/Cell Signaling Technology Inc
    Average 99 stars, based on 1 article reviews
    phosphorylated iκb α - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    Image Search Results


    Effects of BCL on FcRn and related transcription factor expression and ANCA recycling in NCM460 cells. (a,b) FcRn mRNA and protein contents in NCM460 cells with gradient concentrations of BCL treatment for 48 h. Cells with a blank medium treatment were set as a control. (c) Relative recycling of ANCA in NCM460 cells after treatment with the blank medium or 40 μM BCL for 48 h. The relative recycling was calculated with the amount recycled for ANCA compared to that of the control. (d) mRNA contents of p50, p65, IκB, and STAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. (e) Protein contents of p50, p65, IκB, pIκB, STAT1, and pSTAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. All data are expressed as the mean ± SD ( n = 3 replicates/treatment). The protein expression of p50, p65, IκB, pIκB, STAT1, pSTAT1, and the protein/mRNA expression levels of FcRn were normalized to those of GAPDH or β-actin. n.s represents the differences that were not statistically significant ( p > 0.05). */# represent p < 0.05; ** represents p < 0.01; *** represents p < 0.001 against the control.

    Journal: ACS Omega

    Article Title: Baicalein Ameliorates Experimental Ulcerative Colitis Recurrency by Downregulating Neonatal Fc Receptor via the NF-κB Signaling Pathway

    doi: 10.1021/acsomega.5c00243

    Figure Lengend Snippet: Effects of BCL on FcRn and related transcription factor expression and ANCA recycling in NCM460 cells. (a,b) FcRn mRNA and protein contents in NCM460 cells with gradient concentrations of BCL treatment for 48 h. Cells with a blank medium treatment were set as a control. (c) Relative recycling of ANCA in NCM460 cells after treatment with the blank medium or 40 μM BCL for 48 h. The relative recycling was calculated with the amount recycled for ANCA compared to that of the control. (d) mRNA contents of p50, p65, IκB, and STAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. (e) Protein contents of p50, p65, IκB, pIκB, STAT1, and pSTAT1 in NCM460 cells after treatment with blank medium or 40 μM BCL for 48 h. All data are expressed as the mean ± SD ( n = 3 replicates/treatment). The protein expression of p50, p65, IκB, pIκB, STAT1, pSTAT1, and the protein/mRNA expression levels of FcRn were normalized to those of GAPDH or β-actin. n.s represents the differences that were not statistically significant ( p > 0.05). */# represent p < 0.05; ** represents p < 0.01; *** represents p < 0.001 against the control.

    Article Snippet: The membrane was blocked with 5% nonfat milk and incubated with the primary antibody overnight at 4 °C, followed by incubation with the secondary antibody for 1 h. Antibodies against FcRn, p50, p65, IκB, phosphorylated IκB (pIκB), STAT1, phosphorylated STAT1 (pSTAT1), protein arginine deiminase-4 (PAD4), GAPDH, and β actin were obtained from ABclonal Technology (Wuhan, China).

    Techniques: Expressing, Control

    Effects of BCL on FcRn mRNA or protein expression in NCM460 cells with related transcription factors deficiency. (a–c) FcRn, p50, and p65 protein contents in NCM460 cells treated with blank medium or 40 μM BCL for 48 h in the presence or absence of p50 and p65-targeted siRNA. (d,e) FcRn and STAT1 protein contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of STAT1-targeted siRNA. (f–h) FcRn, p50, and p65 mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of p50 and p65-targeted siRNA. (i,j) FcRn and STAT1 mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of STAT1-targeted siRNA. (k) FcRn mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of p50 and p65-targeted siRNA with or without TNF-α (50 ng/mL) stimulation. (l) FcRn mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of STAT1-targeted siRNA with or without IFN-γ (50 ng/mL) stimulation. All data are expressed as the mean ± SD ( n = 3 replicates/treatment). The mRNA or protein expression of FcRn, p50, p65, and STAT1 were normalized to those of GAPDH. Δ represents p < 0.05; **/##/ΔΔ represents p < 0.01; ***/###/ΔΔΔ represents p < 0.001; n.s represents the differences that were not statistically significant ( p > 0.05).

    Journal: ACS Omega

    Article Title: Baicalein Ameliorates Experimental Ulcerative Colitis Recurrency by Downregulating Neonatal Fc Receptor via the NF-κB Signaling Pathway

    doi: 10.1021/acsomega.5c00243

    Figure Lengend Snippet: Effects of BCL on FcRn mRNA or protein expression in NCM460 cells with related transcription factors deficiency. (a–c) FcRn, p50, and p65 protein contents in NCM460 cells treated with blank medium or 40 μM BCL for 48 h in the presence or absence of p50 and p65-targeted siRNA. (d,e) FcRn and STAT1 protein contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of STAT1-targeted siRNA. (f–h) FcRn, p50, and p65 mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of p50 and p65-targeted siRNA. (i,j) FcRn and STAT1 mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of STAT1-targeted siRNA. (k) FcRn mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of p50 and p65-targeted siRNA with or without TNF-α (50 ng/mL) stimulation. (l) FcRn mRNA contents in NCM460 cells treated with a blank medium or 40 μM BCL for 48 h in the presence or absence of STAT1-targeted siRNA with or without IFN-γ (50 ng/mL) stimulation. All data are expressed as the mean ± SD ( n = 3 replicates/treatment). The mRNA or protein expression of FcRn, p50, p65, and STAT1 were normalized to those of GAPDH. Δ represents p < 0.05; **/##/ΔΔ represents p < 0.01; ***/###/ΔΔΔ represents p < 0.001; n.s represents the differences that were not statistically significant ( p > 0.05).

    Article Snippet: The membrane was blocked with 5% nonfat milk and incubated with the primary antibody overnight at 4 °C, followed by incubation with the secondary antibody for 1 h. Antibodies against FcRn, p50, p65, IκB, phosphorylated IκB (pIκB), STAT1, phosphorylated STAT1 (pSTAT1), protein arginine deiminase-4 (PAD4), GAPDH, and β actin were obtained from ABclonal Technology (Wuhan, China).

    Techniques: Expressing

    Effects of BCL on colonic FcRn and related transcription factor expression in mice with UC. (a,b) Colonic FcRn mRNA and protein contents in UC mice after SASP and BCL administration for 7 and 28 days. (c) Protein contents of colonic m-p50, m-p65, iκb, piκb, stat1, and pstat1 in UC mice after SASP and BCL administration for 28 days. All data are expressed as the mean ± SD ( n = 6 replicates/treatment). Mice administrated with UP water were used as the control (UC group). The protein expression of m-p50, m-p65, iκb, piκb, stat1, pstat1, and the protein/mRNA expression levels of FcRn were normalized to those of gapdh or β actin. * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001; n.s represents the differences that were not statistically significant ( p > 0.05).

    Journal: ACS Omega

    Article Title: Baicalein Ameliorates Experimental Ulcerative Colitis Recurrency by Downregulating Neonatal Fc Receptor via the NF-κB Signaling Pathway

    doi: 10.1021/acsomega.5c00243

    Figure Lengend Snippet: Effects of BCL on colonic FcRn and related transcription factor expression in mice with UC. (a,b) Colonic FcRn mRNA and protein contents in UC mice after SASP and BCL administration for 7 and 28 days. (c) Protein contents of colonic m-p50, m-p65, iκb, piκb, stat1, and pstat1 in UC mice after SASP and BCL administration for 28 days. All data are expressed as the mean ± SD ( n = 6 replicates/treatment). Mice administrated with UP water were used as the control (UC group). The protein expression of m-p50, m-p65, iκb, piκb, stat1, pstat1, and the protein/mRNA expression levels of FcRn were normalized to those of gapdh or β actin. * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001; n.s represents the differences that were not statistically significant ( p > 0.05).

    Article Snippet: The membrane was blocked with 5% nonfat milk and incubated with the primary antibody overnight at 4 °C, followed by incubation with the secondary antibody for 1 h. Antibodies against FcRn, p50, p65, IκB, phosphorylated IκB (pIκB), STAT1, phosphorylated STAT1 (pSTAT1), protein arginine deiminase-4 (PAD4), GAPDH, and β actin were obtained from ABclonal Technology (Wuhan, China).

    Techniques: Expressing, Control